{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostate-cancer/diagnosis/psa-testing/","result":{"pageContext":{"chapter":{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing","depth":2,"htmlHeader":"<!-- begin field 6605abfc-4ee7-4cf4-8129-7687f63b3162 --><h2>Information about PSA testing</h2><!-- end field 6605abfc-4ee7-4cf4-8129-7687f63b3162 -->","summary":"","htmlStringContent":"<!-- begin item 227393d6-dee6-4190-9cd9-d88518ccffdc --><!-- end item 227393d6-dee6-4190-9cd9-d88518ccffdc -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","lastRevised":"Last revised in October 2017","chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","fullItemName":"Management","slug":"management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"56ba89f6-57bc-571f-9c06-eff72af94d2a","slug":"psa-testing","fullItemName":"PSA testing","depth":3,"htmlHeader":"<!-- begin field ddb32a8c-add8-44e0-8a6b-a7ba00f77e2c --><h3>What is PSA testing?</h3><!-- end field ddb32a8c-add8-44e0-8a6b-a7ba00f77e2c -->","summary":null,"htmlStringContent":"<!-- begin item 03bfb85f-5904-49be-a20e-a7ba00f779a7 --><!-- begin field 41d5a843-970f-4a2a-a561-a7ba00f77e2c --><ul><li><strong>Prostate-specific antigen (PSA)</strong><ul><li>PSA is a protein produced by normal and cancerous prostate cells.</li><li>PSA is secreted by prostate epithelial cells into prostatic fluid, where its function is to liquefy semen and thus allow spermatozoa to move more freely.</li><li>Although PSA is secreted into prostatic fluid and semen, small amounts of PSA are present in blood. </li></ul></li><li><strong>PSA test</strong><ul><li>As a result of altered prostate architecture in prostate cancer, more PSA leaks out increasing the levels in the blood.<ul><li>However, blood PSA is an inaccurate marker for prostate cancer, because cancer can be present without increased PSA levels, and there are many other causes of increased PSA levels (for example, benign prostatic enlargement, prostatitis, and urinary tract infection).</li></ul></li><li>For information on the limitations of the PSA test for detecting prostate cancer, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/diagnosis/psa-testing/#advice-about-psa-testing\">Benefits and harms of PSA tests</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BMJ, 2017</a>]</p><!-- end field 41d5a843-970f-4a2a-a561-a7ba00f77e2c --><!-- end item 03bfb85f-5904-49be-a20e-a7ba00f779a7 -->","subChapters":[]},{"id":"a5ae2079-85ed-5408-a990-2394be6deb0e","slug":"when-to-offer-psa-testing","fullItemName":"When to offer PSA testing","depth":3,"htmlHeader":"<!-- begin field cd17a5dc-6801-425a-a6d0-a75400ed2c78 --><h3>When should I offer PSA testing for prostate cancer?</h3><!-- end field cd17a5dc-6801-425a-a6d0-a75400ed2c78 -->","summary":null,"htmlStringContent":"<!-- begin item 51f683d6-758f-45d5-93d9-a75400ed2cbf --><!-- begin field 180147b0-2b9d-4a98-a0ee-a75400ed2c78 --><ul><li><strong>Before offering prostate-specific antigen (PSA) testing, ensure that the man has carefully considered the <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/diagnosis/psa-testing/#advice-about-psa-testing\">benefits and limitations&nbsp;of PSA tests</a>.</strong></li><li><strong>Offer PSA testing to:</strong><ul><li>Men older than 50 years of age who request a PSA test.</li></ul></li><li><strong>Consider a PSA test in men with:</strong><ul><li>Lower urinary tract symptoms (LUTS), such as nocturia, urinary frequency, hesitancy, urgency or retention.</li><li>Erectile dysfunction.</li><li>Visible haematuria. </li><li>Unexplained symptoms that could be due to advanced prostate cancer (for example lower back pain, bone pain, weight loss).</li></ul></li><li>Routine screening for prostate cancer is not national policy because the benefits have not been shown to clearly outweigh the harms.<ul><li>PSA testing should not be offered to asymptomatic men.</li></ul></li></ul><!-- end field 180147b0-2b9d-4a98-a0ee-a75400ed2c78 --><!-- end item 51f683d6-758f-45d5-93d9-a75400ed2cbf -->","subChapters":[]},{"id":"887c4111-0b5e-5613-b1ac-986714e2249f","slug":"advice-about-psa-testing","fullItemName":"Advice about PSA testing","depth":3,"htmlHeader":"<!-- begin field 6f14d120-36f4-4a1b-9598-a75400ed43c6 --><h3>What advice should I provide men about PSA testing?</h3><!-- end field 6f14d120-36f4-4a1b-9598-a75400ed43c6 -->","summary":null,"htmlStringContent":"<!-- begin item 5137736e-afc5-4d79-a574-a75400ed4331 --><!-- begin field 439986a4-d026-42e2-8378-a75400ed43c6 --><ul></ul><ul><li>Before the man makes a decision about prostate-specific antigen (PSA) testing, advise him about the: <ul><li><strong>Benefits of PSA testing, including:</strong><ul><li><strong>Early detection </strong>— PSA testing may lead to prostate cancer being detected before symptoms develop.</li><li><strong>Early treatment</strong> — detecting prostate cancer early before symptoms develop may extend life, or facilitate a complete cure.</li></ul></li><li><strong>Limitations and risks of PSA testing, including: </strong><ul><li><strong>False-negative PSA tests</strong> — about 15% of men with a negative PSA test may have prostate cancer, and 2% will have high-grade cancer. However, it is not known what proportion of these cancers become clinically evident.</li><li><strong>False-positive PSA tests</strong> — about 75% of men with a positive PSA test have a negative prostate biopsy.</li><li><strong>Unnecessary investigation</strong><strong> </strong>— a false positive PSA test may lead to invasive investigations, such as prostate biopsy, and there may be adverse effects (for example bleeding, or infection).</li><li><strong>Unnecessary treatment</strong> — a positive PSA test may lead to the identification and treatment of prostate cancers which would not have become clinically evident during the man’s lifetime. Adverse effects of treatment are common and serious and include urinary incontinence and sexual dysfunction.</li></ul></li></ul></li><li>Advise men who are considering a PSA test about <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/diagnosis/psa-testing/#decision-aids-for-men-considering-a-psa-test\">decision aids</a> and online <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/diagnosis/psa-testing/#information-resources-on-psa-testing\">sources of information</a>.</li></ul><!-- end field 439986a4-d026-42e2-8378-a75400ed43c6 --><!-- end item 5137736e-afc5-4d79-a574-a75400ed4331 -->","subChapters":[]},{"id":"690517a0-bc7a-562a-875e-16d86e7eae38","slug":"decision-aids-for-men-considering-a-psa-test","fullItemName":"Decision aids for men considering a PSA test","depth":3,"htmlHeader":"<!-- begin field 3a3de9d2-b3b9-46e6-a45d-a75400ed619b --><h3>What decision aids are there for men considering a PSA test?</h3><!-- end field 3a3de9d2-b3b9-46e6-a45d-a75400ed619b -->","summary":null,"htmlStringContent":"<!-- begin item 9cc20443-69c8-49a8-b97a-a75400ed61d4 --><!-- begin field 6230d0ba-2353-48e6-962b-a75400ed619b --><ul><li>Decision aids have been developed for men considering having a prostate-specific antigen (PSA) test. They provide background information about the prostate and prostate cancer, information about risk factors for prostate cancer, and information on uncertainties when interpreting PSA results and deciding on treatment. They include:<ul><li>A Public Health England (PHE) patient information sheet <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/509191/Patient_info_sheet.pdf\" data-hyperlink-id=\"f5e6227b-7569-4075-b756-a93100a6f3c2\">PSA testing and prostate cancer: advice for well men aged 50 and over</a>.</li><li>An online NHS Right Care decision aid<strong> </strong><a href=\"http://sdm.rightcare.nhs.uk/pda/psa-testing/\" data-hyperlink-id=\"ce40790b-b19a-440d-aef4-a93100a6f43d\">Deciding whether to have a prostate specific antigen (PSA) test</a>. </li><li><a href=\"http://www.prostatecancer-riskcalculator.com/\" data-hyperlink-id=\"74276e66-f49a-4558-b1bc-a93100a6f495\">SWOP</a> — an online decision aid developed by the Department of Urology of the Erasmus MC, the University and Medical Centre of Rotterdam in the Netherlands. It is organized around graphical displays of the man's risk of prostate cancer. </li></ul></li></ul><!-- end field 6230d0ba-2353-48e6-962b-a75400ed619b --><!-- end item 9cc20443-69c8-49a8-b97a-a75400ed61d4 -->","subChapters":[]},{"id":"d4210c00-ad5b-5ae3-b5e5-ba287b2644a8","slug":"information-resources-on-psa-testing","fullItemName":"Information resources on PSA testing","depth":3,"htmlHeader":"<!-- begin field 3218409f-8429-476e-81b9-a75400ed6d34 --><h3>Where can men obtain information about PSA testing?</h3><!-- end field 3218409f-8429-476e-81b9-a75400ed6d34 -->","summary":null,"htmlStringContent":"<!-- begin item c0b14462-7217-43b8-a14f-a75400ed6c60 --><!-- begin field 7abffbd2-9a36-4a6d-8628-a75400ed6d34 --><ul><li><strong>Cancer Research UK</strong> provides information for people with all forms of cancer. The website includes information on risks, symptoms, diagnosis and treatment of prostate cancer as well as practical and emotional support.  <ul><li>Visit <a data-hyperlink-id=\"5594b55c-d962-4bc5-a7e1-a93100cf691d\" href=\"http://www.cancerresearchuk.org/about-cancer/prostate-cancer\">www.cancerresearchuk.org</a>. </li></ul></li><li><strong>Healthtalkonline</strong> provides information about PSA testing and prostate cancer, as well as the personal experiences of men with prostate cancer. <ul><li>Visit <a data-hyperlink-id=\"9d5be762-6d1d-4515-9075-a93100cf6a2d\" href=\"http://www.healthtalkonline.org/Cancer/Prostate_Cancer\">www.healthtalkonline.org</a>.</li></ul></li><li><strong>Prostate Cancer UK</strong> produces a wide range of publications for health professionals to use when discussing diagnostic tests, treatments, and adverse effects with their patients.<ul><li>Publications that can be downloaded for printing include:<ul><li><a data-hyperlink-id=\"aadc0883-0dd2-4a17-9f85-a93100cf6f95\" href=\"https://prostatecanceruk.org/prostate-information/our-publications/publications/know-your-prostate-a-guide-to-common-prostate-problems\">Know your prostate: a guide to common prostate problems</a>.</li><li><a data-hyperlink-id=\"7dfe4019-5981-46ff-8365-a93100cf71c6\" href=\"https://prostatecanceruk.org/prostate-information/our-publications/publications/the-psa-test-and-prostate-cancer-a-quick-guide\">The PSA test and prostate cancer: a quick guide</a>. </li><li><a data-hyperlink-id=\"ae04450b-b457-4f2f-b54b-a93100cf72fc\" href=\"http://prostatecanceruk.org/media/41612/1846-african-caribbean-leaflet_for-web.pdf\">What do you know about your prostate? Information for black men</a>.</li></ul></li><li>Visit <a data-hyperlink-id=\"d2a3508d-8c02-4d80-ab4f-a93100cf7313\" href=\"http:// www.prostatecanceruk.org/\">www.prostatecanceruk.org</a>.</li></ul></li><li><strong>Macmillan Cancer Support </strong>aims to improve the lives of people affected by cancer by providing practical, medical, and financial support.<ul><li>Information on prostate cancer, including how it is diagnosed, treatments that might be given, possible side effects, and how to get further support, can be found at <a data-hyperlink-id=\"7cd27f2f-e23e-489a-8ca8-a93100cf7331\" href=\"http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Prostatecancer.aspx\">www.macmillan.org.uk</a>.</li></ul></li><li><strong>NHS Health A-Z</strong> is a comprehensive health information service, which includes information on prostate cancer.<ul><li>Visit <a data-hyperlink-id=\"69860943-7785-42de-9baa-a93100cf73ae\" href=\"http://www.nhs.uk/Conditions/Cancer-of-the-prostate/Pages/Prevention.aspx\">www.nhs.uk</a>.</li></ul></li><li><strong>Prostate Cancer Infolink </strong>provides information for patients and their families. <ul><li>Visit <a data-hyperlink-id=\"e8545ea9-e9fe-4c5a-8ec3-a93100cf747c\" href=\"https://prostatecancerinfolink.net/\">prostatecancerinfolink.net</a>.</li></ul></li></ul><!-- end field 7abffbd2-9a36-4a6d-8628-a75400ed6d34 --><!-- end item c0b14462-7217-43b8-a14f-a75400ed6c60 -->","subChapters":[]},{"id":"bad692df-7f67-520c-aaeb-281920f34636","slug":"psa-test-practicalities","fullItemName":"PSA test practicalities","depth":3,"htmlHeader":"<!-- begin field 3a56adc2-9c3d-41d0-9e22-a75400ed386c --><h3>What practicalities are involved in PSA testing?</h3><!-- end field 3a56adc2-9c3d-41d0-9e22-a75400ed386c -->","summary":null,"htmlStringContent":"<!-- begin item 1a4d6367-07d3-4c64-8d70-a75400ed38bf --><!-- begin field 3b6f8c87-c5bd-41d3-81cd-a75400ed386c --><ul><li>Since prostate-specific antigen (PSA) levels are likely to be increased, men should not have a PSA test if they have: <ul><li>An active urinary infection (PSA may remain raised for many months).</li><li>Had a prostate biopsy in the previous 6 weeks.</li><li>Exercised vigorously in the last 48 hours.  </li><li>Ejaculated in the last 48 hours.</li></ul></li><li>The specimen must reach the laboratory within 16 hours.</li></ul><!-- end field 3b6f8c87-c5bd-41d3-81cd-a75400ed386c --><!-- end item 1a4d6367-07d3-4c64-8d70-a75400ed38bf -->","subChapters":[]},{"id":"e5928403-9428-5b49-aff3-4fa2767904c4","slug":"managing-psa-results","fullItemName":"Managing PSA results","depth":3,"htmlHeader":"<!-- begin field b045aff5-6d65-42dc-baca-a75400ed57e8 --><h3>How should I interpret and manage PSA results?</h3><!-- end field b045aff5-6d65-42dc-baca-a75400ed57e8 -->","summary":null,"htmlStringContent":"<!-- begin item da9296ca-d0b2-47ac-998d-a75400ed5755 --><!-- begin field 0c5f7804-4da4-4815-a47a-a75400ed57e8 --><ul><li>A normal prostate-specific antigen (PSA) level ranges from 0–4 nanograms/mL. However, the upper level of normal may vary according to age and race, and the PSA test is not diagnostic. <ul><li>Men with an elevated PSA may need further investigation, for example a biopsy.</li></ul></li><li>If the prostate-specific antigen (PSA) level in men (of any race) aged 50–69 years is:<ul><li><strong>3.0 nanogram/mL or higher</strong> — refer men urgently using a suspected cancer pathway referral (for an appointment within 2 weeks) to a specialist. </li><li><strong>Within the normal range for this age group (that is lower than 3.0 nanograms/ml)</strong> — there is a low risk of prostate cancer. <ul><li>Refer only if there are other concerns, for example factors that increase the risk of prostate cancer, or an abnormal digital rectal examination (DRE).</li></ul></li></ul></li><li>Clinical judgement should be used to manage symptomatic men and those aged under 50 who are considered to have a higher risk for prostate cancer.</li></ul><!-- end field 0c5f7804-4da4-4815-a47a-a75400ed57e8 --><!-- end item da9296ca-d0b2-47ac-998d-a75400ed5755 -->","subChapters":[]},{"id":"0cc94c9f-61f4-59cb-abc1-317ea5362d50","slug":"basis-for-recommendation-9b6","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 041070c4-9353-4719-9529-a7a7013d19a1 --><h3>Basis for recommendation</h3><!-- end field 041070c4-9353-4719-9529-a7a7013d19a1 -->","summary":null,"htmlStringContent":"<!-- begin item 9b6c30bb-ffcf-477a-8bb3-a7a7013d0f2f --><!-- begin field cd075ec4-24ee-4547-830b-a7a7013d19a1 --><p>These recommendations are based on the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>], the National Institute for Health and Care Excellence (NICE) guidelines <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2015a</a>], <em>Lower urinary tract symptoms in men: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2015c</a>], and <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>], and the British Medical Journal (BMJ) best practice guide <em>Prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BMJ, 2017</a>].</p><h4>Decision aids for men considering a PSA test</h4><ul><li>The National Institute for Health and Care Excellence (NICE) recommends that men with prostate cancer should receive information about the benefits and limitations of tests and treatments, but does not recommend specific resources [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].<ul><li>The resources listed have been identified by CKS.</li></ul></li></ul><h4>Managing PSA results </h4><ul><li><p>These recommendations reflect guidelines from the<em> UK National Screening Committee Screening for prostate cancer review 2015 update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">UKNSC, 2015</a>] and Public Health England's <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</p></li><li><p>Previously, age-related cut-offs were recommended. However, an updated review of the literature shows that age-specific prostate-specific antigen (PSA) cut-offs for detecting prostate cancer are highly variable and may reflect differences in demographics and clinical characteristics in a population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</p></li></ul><!-- end field cd075ec4-24ee-4547-830b-a7a7013d19a1 --><!-- end item 9b6c30bb-ffcf-477a-8bb3-a7a7013d0f2f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}